Buspirone Generic Approvals Expected By End Of February After Patent Ruling
Executive Summary
FDA is expected to approve additional generics of buspirone by the end of the month following a court ruling throwing out Bristol-Myers Squibb's late-listed BuSpar patent
You may also be interested in...
AARP Eyeing AWP Lawsuits After Joining Generic Competition Cases
AARP's next area for pharmaceutical litigation may be joining state lawsuits regarding reporting of average wholesale prices
AARP Eyeing AWP Lawsuits After Joining Generic Competition Cases
AARP's next area for pharmaceutical litigation may be joining state lawsuits regarding reporting of average wholesale prices
FTC To Testify On Generic Reform; Agency Report May Be “Months” Away
Patent licensing deals that relate exclusively to listing in FDA's "Orange Book" will attract antitrust scrutiny, FTC Office of Policy Planning Director Ted Cruz said